A phase 3 randomized double-blind comparison of ceftobiprole medocaril versus ceftazidime plus linezolid for the treatment of hospital-acquired pneumonia

Clinical Infectious Diseases

Volumn 59, Issue 1, 2014, Pages 51-61

  Awad, Samir S ^a   Rodriguez, Alejandro H ^b   Chuang, Yin Ching ^c   Marjanek, Zsuszanna ^d   Pareigis, Alex J ^e   Reis, Gilmar ^f   Scheeren, Thomas W L ^g,h   Sánchez, Alejandro S ⁱ   Zhou, Xin ^j   Saulay, Mikaël ^k   Engelhardt, Marc ^l  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b HOSPITAL UNIVERSITARI JOAN XXIII   (Spain)

^c CHI MEI MEDICAL CENTER   (Taiwan)

^d Javorsky Ödön City Hospital   (Hungary)

^e Medical Arts Associates Ltd   (United States)

^f Santa Casa de Belo Horizonte ^*  (Brazil)

^g UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^h ROSTOCK UNIVERSITY MEDICAL CENTER   (Germany)

ⁱ Policlínico Modelo de Cipolletti   (Argentina)

^j SHANGHAI FIRST PEOPLE S HOSPITAL   (China)

^k ICON PLC   (United Kingdom)

^l BASILEA PHARMACEUTICA INTERNATIONAL LTD   (Switzerland)

more..

Author keywords

ceftazidime; ceftobiprole; hospital acquired pneumonia; linezolid; ventilator associated pneumonia

Indexed keywords

CEFTAZIDIME; CEFTOBIPROLE MEDOCARIL; LINEZOLID; ACETAMIDE DERIVATIVE; ANTIINFECTIVE AGENT; CEPHALOSPORIN DERIVATIVE; OXAZOLIDINONE DERIVATIVE;

ADULT; AGED; APACHE; ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HOSPITAL ACQUIRED PNEUMONIA; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; NONHUMAN; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; VENTILATOR ASSOCIATED PNEUMONIA; YOUNG ADULT; ADOLESCENT; CLINICAL TRIAL; CROSS INFECTION; INTRAVENOUS DRUG ADMINISTRATION; PNEUMONIA, BACTERIAL; PROCEDURES; VERY ELDERLY;

ACETAMIDES; ADMINISTRATION, INTRAVENOUS; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; CEFTAZIDIME; CEPHALOSPORINS; CROSS INFECTION; DOUBLE-BLIND METHOD; DRUG THERAPY; FEMALE; HUMANS; LINEZOLID; MALE; MIDDLE AGED; OXAZOLIDINONES; PNEUMONIA, BACTERIAL; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84902958324     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciu219     Document Type: Article

References (37)

1. Torres A, Ferrer M, Badia JR. Treatment guidelines and outcomes of hospital-acquired and ventilator-associated pneumonia. Clin Infect Dis 2010; 51(suppl 1):S48-53.
2. Masterton R. The place of guidelines in hospital-acquired pneumonia. J Hosp Infect 2007; 66:116-22.
3. Jones RN. Microbial etiologies of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Clin Infect Dis 2010; 51(suppl 1):S81-7.
4. Lovering AL, Gretes MC, Safadi SS, et al. Structural insights into the anti-methicillin-resistant Staphylococcus aureus (MRSA) activity of ceftobiprole. J Biol Chem 2012; 287:32096-102.
5. Davies TA, Page MG, Shang W, Andrew T, Kania M, Bush K. Binding of ceftobiprole and comparators to the penicillin binding proteins of Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and Streptococcus pneumoniae. Antimicrob Agents Chemother 2007; 51:2621-4.
6. Bogdanovich T, Ednie LM, Appelbaum PC, Shapiro S. Antistaphylococcal activity of ceftobiprole, a new broad-spectrum cephalosporin. Antimicrob Agents Chemother 2005; 49:4210-9.
7. Flamm RK, Sader HS, Streit JM, Jones RN. Activity of ceftobiprole tested against gram-negative clinical isolates from European medical centres [abstract P1627]. In: Programme and abstracts of the 23rd European Congress of Clinical Microbiology and Infectious Diseases (Berlin, Germany). Basel, Switzerland: European Society of Clinical Microbiology and Infectious Diseases, 2013.
8. Flamm RK, Sader HS, Streit JM, Jones RN. Activity of ceftobiprole tested against clinical isolates of staphylococci and streptococci from European surveillance (2008-2010) [abstract P1628]. In: Programme and abstracts of the 23rd European Congress of Clinical Microbiology and Infectious Diseases (Berlin, Germany). Basel, Switzerland: European Society of Clinical Microbiology and Infectious Diseases, 2013.
9. Germel C, Haag A, Söderquist B. In vitro activity of beta-lactam antibiotics to community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA). Eur J Clin Microbiol Infect Dis 2012; 31:475-80.
10. Denis O, Deplano A, Nonhoff C, et al. In vitro activities of ceftobiprole, tigecycline, daptomycin, and 19 other antimicrobials against methicillin-resistant Staphylococcus aureus strains from a national survey of Belgian hospitals. Antimicrob Agents Chemother 2006; 50:2680-5.
11. Amsler KM, Davies TA, Shang W, Bush K, Jacobs MR. In vitro activity of ceftobiprole against pathogens from two phase 3 clinical trials of complicated skin and skin structure infections. Antimicrob Agents Chemother 2008; 52:3418-23.
12. Zhanel GG, Lam A, Thomson K, et al. Ceftobiprole: a review of a broadspectrum and anti-MRSA cephalosporin. Am J Clin Dermatol 2008; 9:245-54.
13. Betriu C, Culebras E, Gómez M, et al. Comparative in vitro activity of ceftobiprole against gram-positive cocci. Int J Antimicrob Agents 2010; 36:111-13.
14. Flamm RK, Sader HS, Streit JM, Jones RN. Activity of ceftobiprole tested against pathogens associated with hospital-acquired bacterial pneumonia in Europe [abstract P1625]. In: Programme and abstracts of the 23rd European Congress of Clinical Microbiology and Infectious Diseases (Berlin, Germany). Basel, Switzerland: European Society of Clinical Microbiology and Infectious Diseases, 2013.
15. Flamm RK, Sader HS, Streit JM, Jones RN. Activity of ceftobiprole against methicillin-resistant Staphylococcus aureus including strains with reduced susceptibility to daptomycin, linezolid, and vancomycin [abstract P1629]. In: Programme and abstracts of the 23rd European Congress of Clinical Microbiology and Infectious Diseases (Berlin, Germany). Basel, Switzerland: European Society of Clinical Microbiology and Infectious Diseases, 2013.
16. Davies TA, Flamm RK, Lynch AS. Activity of ceftobiprole against Streptococcus pneumoniae isolates exhibiting high-level resistance to ceftriaxone. Int J Antimicrob Agents 2012; 39:534-8.
17. Davies TA, Shang W, Bush K. Activities of ceftobiprole and other betalactams against Streptococcus pneumoniae clinical isolates from the United States with defined substitutions in penicillin-binding proteins PBP 1a, PBP 2b, and PBP 2x. Antimicrob Agents Chemother 2006; 50:2530-2.
18. Tattevin P, Basuino L, Bauer D, Diep BA, Chambers HF. Ceftobiprole is superior to vancomycin, daptomycin, and linezolid for treatment of experimental endocarditis in rabbits caused by methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2010; 54:610-3.
19. Chambers HF. Evaluation of ceftobiprole in a rabbit model of aortic valve endocarditis due to methicillin-resistant and vancomycin-intermediate Staphylococcus aureus. Antimicrob Agents Chemother 2005; 49:884-8.
20. Saleh-Mghir A, Dumitrescu O, Dinh A, et al. Ceftobiprole efficacy in vitro against Panton-Valentine leukocidin production and in vivo against community-associated methicillin-resistant Staphylococcus aureus osteomyelitis in rabbits. Antimicrob Agents Chemother 2012; 56:6291-7.
21. Yin LY, Calhoun JH, Thomas JK, Shapiro S, Schmitt-Hoffmann A. Efficacies of ceftobiprole medocaril and comparators in a rabbit model of osteomyelitis due to methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2008; 52:1618-22.
22. Stucki A, Cottagnoud M, Acosta F, Egerman U, Läuffer J, Cottagnoud P. Evaluation of ceftobiprole activity against a variety of gram-negative pathogens, including Escherichia coli, Haemophilus influenzae (β-lactamase positive and β-lactamase negative), and Klebsiella pneumoniae, in a rabbit meningitis model. Antimicrob Agents Chemother 2012; 56:921-5.
23. Barnea Y, Navon-Venezia S, Kuzmenko B, Artzi N, Carmeli Y. Ceftobiprole medocaril is an effective treatment against methicillin-resistant Staphylococcus aureus (MRSA) mediastinitis in a rat model. Eur J Clin Microbiol Infect Dis 2014; 33:325-9.
24. Arias CA, Singh KV, Murray BE, et al. Evaluation of ceftobiprole medocaril against Enterococcus faecalis in a mouse peritonitis model. J Antimicrob Chemother 2007; 60:594-8.
25. Hilliard JJ, Melton JL, Flamm RK, Bush K. Efficacy of ceftobiprole against Streptococcus pneumoniae in a murine lower respiratory tract infection model [abstract A-036]. In: Programme and abstracts of the 48th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, 2008. Raritan, NJ: Johnson & Johnson Pharmaceutical Research and Devevelopment.
26. Fernandez J, Hilliard JJ, Abbanat D, et al. In vivo activity of ceftobiprole in murine skin infections due to Staphylococcus aureus and Pseudomonas aeruginosa. Antimicrob Agents Chemother 2010; 54:116-25.
27. Nicholson SC, Welte T, File TM Jr, et al. A double-blind trial comparing ceftobiprole medocaril with ceftriaxone with or without linezolid for the treatment of patients with community-acquired pneumonia requiring hospitalisation. Int J Antimicrob Agents 2012; 39:240-6.
28. Committee for Medicinal Products for Human Use (CHMP). Addendum to the note for guidance on evaluation of medicinal products indicated for treatment of bacterial infections (CPMP/EWP/558/95 REV 2) to address indication-specific clinical data. European Medicines Agency EMA/CHMP/776609/2011; 2012.
29. Center for Drug Evaluation and Research. Guidance for industry: hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia: developing drugs for treatment. US Food and Drug Administration, 2010; Revision 1.
30. Rubinstein E, Lalani T, Corey GR, et al. Telavancin versus vancomycin for hospital-acquired pneumonia due to gram-positive pathogens. Clin Infect Dis 2011; 52:31-40.
31. Réa-Neto A, Niederman M, Lobo SM, et al. Efficacy and safety of doripenem versus piperacillin/tazobactam in nosocomial pneumonia: a randomized, open-label, multicenter study. Curr Med Res Opin 2008; 24:2113-26.
32. Freire AT, Melnyk V, Kim MJ, et al.; the 311 Study Group. Comparison of tigecycline with imipenem/cilastatin for the treatment of hospitalacquired pneumonia. Diagn Microbiol Infect Dis 2010; 68:140-51.
33. Zanetti G, Bally F, Greub G, et al. Cefepime Study Group. Cefepime versus imipenem-cilastatin for treatment of nosocomial pneumonia in intensive care unit patients: a multicenter, evaluator-blind, prospective, randomized study. Antimicrob Agents Chemother 2003; 47: 3442-7.
34. Muscedere JG, Day A, Heyland DK. Mortality, attributable mortality, and clinical events as end points for clinical trials of ventilatorassociated pneumonia and hospital-acquired pneumonia. Clin Infect Dis 2010; 51(suppl 1):S120-5.
35. Napolitano LM. Use of severity scoring and stratification factors in clinical trials of hospital-acquired and ventilator-associated pneumonia. Clin Infect Dis 2010; 51(suppl 1):67-80.
36. Nguile-Makao M, Zahar JR, Français A, et al. Attributable mortality of ventilator-associated pneumonia: respective impact of main characteristics at ICU admission and VAP onset using conditional logistic regression and multi-state models. Intensive Care Med 2010; 36:781-9.
37. Muller AE, Schmitt-Hoffmann AH, Punt N, Mouton JW. Monte Carlo simulations based on phase 1 studies predict target attainment of ceftobiprole in nosocomial pneumonia patients: a validation study. Antimicrob Agents Chemother 2013; 57:2047-53.